logo
Twitter
Discord
Email
logo
Bruker Corporation

Bruker Corporation

NASDAQ•BRKR
CEO: Dr. Frank H. Laukien Ph.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2000-08-04
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Contact Information
40 Manning Road, Billerica, MA, 01821, United States
978-663-3660
www.bruker.com
Market Cap
$7.28B
P/E (TTM)
-367.8
32.2
Dividend Yield
0.4%
52W High
$64.64
52W Low
$28.53
52W Range
54%
Rank31Top 15.1%
5.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$860.50M-0.45%
4-Quarter Trend

EPS

-$0.41-246.82%
4-Quarter Trend

FCF

-$54.10M-1032.76%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth 9M YTD Total revenue reached $2.46B, marking a 3.0% increase over prior period, driven by acquisitions and service revenue.
CALID Segment Revenue Surge BSI CALID revenue increased $105.7M, up 13.7% driven by ELITechGroup and molecular diagnostics volume growth.
Preferred Stock Issuance Completed Issued 2.76M Series A Mandatory Convertible Preferred Stock shares, raising $669.5M net proceeds for debt repayment.
Cash Position Improved Sequentially Ending cash balance $297.3M, up $110.6M sequentially, despite $(95.7)M used in operating activities year-to-date.

Risk Factors

Significant Goodwill Impairment Charge Recorded $96.5M goodwill impairment charge across BSB and AUT units due to fair value falling below carrying amount.
Operating Income Swings Negative Operating income swung to a $(8.1)M loss for nine months, compared to $181.0M income last year period.
Gross Margin Under Pressure Total gross margin fell to 45.9% from 48.4% due to increased restructuring costs and U.S. tariff impacts.
Operating Cash Flow Negative Net cash used in operating activities was $(95.7)M for nine months, compared to $61.3M provided in 2024.

Outlook

Cost Savings Initiative Planned Announced cost savings initiative targeting $100M to $120M annual reduction starting in 2026 across all business parts.
Debt Repayment Utilizing Proceeds Used $669.5M proceeds from preferred stock to fully repay 2019 term loan and outstanding revolving credit balance.
Monitoring Macroeconomic Uncertainties Management monitors geopolitical tensions, tariffs, and funding delays, which may cause future goodwill impairment charges.
Finalizing Acquisition Valuations Finalized valuation for Recipe acquisition; processing tax adjustments for other acquisitions, impacting goodwill balances.

Peer Comparison

Revenue (TTM)

Bausch + Lomb CorporationBLCO
$4.97B
+6.1%
Bruker CorporationBRKR
$3.44B
+6.1%
Teleflex IncorporatedTFX
$3.19B
+5.4%

Gross Margin (Latest Quarter)

TG Therapeutics, Inc.TGTX
86.6%
-2.1pp
Glaukos CorporationGKOS
78.4%
+1.8pp
iRhythm Technologies, Inc.IRTC
71.1%
+2.3pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
KRYS$7.31B36.719.4%0.1%
BRKR$7.28B-367.8-1.0%31.2%
GKOS$6.67B-75.7-11.4%10.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-4.2%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 12, 2026
|
EPS:$0.66
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $860.50M-0.5%
    |
    EPS: $-0.41-246.8%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $797.40M-0.4%
    |
    EPS: $0.05-3.1%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $801.40M+11.0%
    |
    EPS: $0.11-68.6%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 3, 2025|
    Revenue: $3.37B+13.6%
    |
    EPS: $0.76-74.0%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $864.40M+16.4%
    |
    EPS: $0.28-53.3%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 9, 2024|
    Revenue: $800.70M+17.4%
    |
    EPS: $0.05-86.8%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 10, 2024|
    Revenue: $721.70M+5.3%
    |
    EPS: $0.35-32.7%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 29, 2024|
    Revenue: $2.96B+17.1%
    |
    EPS: $2.92+46.0%
    Beat